West Cancer Center & Research Institute is the leader in comprehensive adult cancer care led by providers to provide the most positive outcomes though research, novel therapies, advanced treatments, and cancer prevention to all patients, regardless of socioeconomic status. With over 40 years of oncology expertise, 100+ specialists, 8 locations and over 47,000 patients in 2021- West is positioned as the first choice for cancer care in the Mid-South and a national model for comprehensive care.
Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers
February 25th 2021Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.
Trastuzumab Deruxtecan Slated for Study in HER2+ Gastric/GEJ Cancer
February 15th 2021Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.
Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer
January 4th 2020Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.